Jesus G. Berdeja, MD - Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma With Bispecific Antibodies: A Community Clinician's Roadmap
Please visit answersincme.com/RJB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in multiple myeloma discuss strategies for incorporating bispecific antibodies into the treatment of heavily pretreated relapsed/refractory multiple myeloma RRMM in the community setting. Upon completion of this activity, participants should be better able to: Review the role of bispecific antibodies in the current treatment landscape of RRMM; Discuss the clinical profiles of approved and late-stage emerging bispecific antibodies in heavily pretreated RRMM; Describe strategies to optimize outcomes with bispecific antibodies for the treatment of RRMM; and Outline practical considerations for incorporating bispecific antibodies into the treatment of heavily pretreated RRMM in the community setting. This activity is intended for US healthcare professionals only.
-------- Â
17:14
Aditya Bardia, MD / Sara Hurvitz, MD - Making a World of Difference for Patients With HER2-Low and -Ultralow Advanced Breast Cancer: Practical Strategies to Integrate Antibody-Drug Conjugates in Special Populations
Please visit answersincme.com/860/95483855-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss practical strategies for integrating antibody-drug conjugates in special populations with HER2-low advanced breast cancer and essential adverse event management approaches. Upon completion of this activity, participants should be better able to: Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer; and Outline evidence-based strategies to enhance the management of patients with HER2-low and -ultralow advanced breast cancer.
-------- Â
30:09
Aditya Bardia, MD / Sara Hurvitz, MD - Realizing the Potential of Antibody-Drug Conjugates in HER2-Low and -Ultralow Advanced Breast Cancer: Evolving Strategies to Individualize Care
Please visit answersincme.com/860/95483855-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss antibody-drug conjugates in HER2-low advanced breast cancer, including current guideline recommendations and evolving treatment considerations to optimize individualized care. Upon completion of this activity, participants should be better able to: Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer; and Outline evidence-based strategies to enhance the management of patients with HER2-low and -ultralow advanced breast cancer.
-------- Â
26:25
Komal Jhaveri, MD, FACP - Opportunities to Personalize Care: Making the Case for TROP2-Directed ADCs in HR+, HER2- Metastatic Breast Cancer
Please visit answersincme.com/BCQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer discusses use of TROP2-directed antibody-drug conjugates for the management of hormone receptor–positive, HER2-negative metastatic disease. Upon completion of this activity, participants should be better able to: Identify the available TROP2-directed ADCs for management of HR+, HER2- metastatic breast cancer (mBC); Outline the efficacy and safety of available and emerging TROP2-directed ADCs for HR+, HER2- mBC; and Apply personalization factors to help identify the optimal therapy for each individual patient with HR+, HER2- mBC.
-------- Â
19:18
Aditya Bardia, MD / Marilyn M. Bui, MD, PhD - Bringing HER2 Low and Ultralow to Light: How to Define and Detect HER2 Status in Advanced Breast Cancer
Please visit answersincme.com/860/95483855-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and pathology discuss the evolving classification of HER2 status in advanced breast cancer, including HER2 low and HER2 ultralow, and its impact on treatment decisions. Upon completion of this activity, participants should be better able to: Identify strategies to enhance the identification of HER2-low and -ultralow status in patients with advanced breast cancer; and Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer,
About CME in Minutes: Education in Oncology & Hematology
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
Listen to CME in Minutes: Education in Oncology & Hematology, The School of Greatness and many other podcasts from around the world with the radio.net app
USA